Trubion CEO steps down |
Connect with TechFlash on our Facebook page for all the latest technology news headlines and commentary, plus information and access to special events, photos from events, promotions and more.
Today On Techflash
- Can Microsoft overcome the smartphone app gap?
- Hey recruiters: Here's an R&D lab run by, and for, students
- Apps that waste your time (in a good way): Execs' addictions
- WTIA announces Industry Achievement Award finalists
- Analyst sees 7-inch iPad in Apple future
- Check out this app: Executives list the ones they use most
Mass High Tech
Trubion CEO steps down
Peter Thompson, the chief executive of Seattle biotechnology company Trubion Pharmaceuticals, has stepped down from the post in order to "pursue other interests." He is being replaced on an interim basis for board member and Seattle venture capitalist Steven Gillis, a managing director at Arch Venture Partners.
Shares of Trubion are up 222 percent on the year, but they fell after the news was announced. In addition to Thompson, the company said that Michelle Burris has been promoted from CFO to COO. And John Bencich, formerly director of finance and accounting, has taken on the CFO duties.
Thompson's bio is still on the company's Web site. Prior to co-founding Trubion more than seven years ago, he served as an executive at iMetrikus and Chiron. During his tenure at Trubion, he also served as a venture partner at ATP Capital.
Gillis, who previously served as CEO of Corixa, thanked Thompson for his service in a press release today. "His leadership has been vital to Trubion's successful growth and its scientific, clinical and business achievements, and as a result Trubion today is well-positioned strategically," Gillis said. "Trubion's strategy remains the same -- to focus on the discovery, development and commercialization of leading protein therapeutics for autoimmune and inflammatory diseases and cancer."
Trubion is working on treatments for autoimmune and inflammatory diseases, as well as cancer. It posted revenue of $12.8 million during the first nine months of year, with the bulk of that revenue coming through a partnership with Pfizer. The money-losing company also recently signed a strategic partnership with Facet Biotech for the possible treatment of chronic lymphocytic leukemia.
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
TechFlash Team
Recent Sponsor Posts
Who's creating today's energy efficient buildings? Find out at the BetterBricks Awards, Feb. 16
BetterBricks Awards salute the individuals leading the way for high performance commercial buildings with an emphasis on energy efficiency. Join us as we recognize these standout green building professionals.
Award categories include: Advocate; Architect/Designer; Facility Manager/Operator; and Owner/Developer.
Keynote Speaker: Kevin Kampschroer, Director of U.S. GSA's Office of Federal High Performance Buildings. Kevin leads the U.S. General Services Administration's efforts in building sustainability and accelerating industry adoption of sustainable principles across all aspects of a building's life.
Register here by February 10!
If you are interested in buying a table, email Monica Alquist or call her at 206-876-5404.
The Triple Door Presents: The Atomic Bombshells "J'ADORE!: A Burlesque Valentine"
Seattle's reigning Burlesque super-troupe delivers a gorgeous and glittering VALENTINE featuring some of the Bombshells' most exhilarating acts to date. J'Adore! promises to celebrate l'amour with good humor, style, and a healthy dose of dazzle! Bring a friend, a lover, a family member, or a secret crush, and celebrate with the Valentine's Burlesque spectacular that will leave you shouting: "J'ADORE......The Atomic Bombshells!" The incomparable Jasper McCann emcees with high style and charm.
Please visit www.thetripledoor.net for a full schedule of future performances.
The Triple Door Presents: Bob Mould – See A Little Light: An Evening of Reading and Music
"Bob Mould. Those two words are synonymous with integrity. From Husker Du in the last century to right at this moment, Bob is the real deal, writing and playing music for music's sake. He's a great songwriter and performer. I have been a fan of Bob's for thirty years now with no end in sight." -Henry Rollins
Please visit www.thetripledoor.net for a full schedule of future performances.
Why Choose BDO for your SOC (previously SAS 70) Reports?
BDO’s experience in providing attestation services (SAS 70/SSAE 16, AT 101, AT 201, AT 601, etc.) to a broad range of industries, and our team of skilled professionals distinctly qualifies us to serve as your company’s Service Auditor. By leveraging the BDO global network of control specialists, we are poised to provide global services in more than 1,000 offices and across 119 countries. Many organizations find that investing in reports on controls may result in benefits, including:
• Increased client confidence
• Improved competitive advantage
• Minimization of frequent audits
• Streamlined business processes and controls
• Enhanced risk management
For detailed information contact Paul Martini at pmartini@bdo.com.
